

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/049,464
Filing Date	6/18/2002
First Named Inventor	HUENIG
Group Art Unit	1614
Examiner Name	Unassigned
Attorney Docket Number	ALBRE-23

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]


Ther Auspich

11/08/2005

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 If possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08-00

Approved for use through 10/31/2002. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 2

Complete if Known

Application Number 10/049,464
Filing Date 06-18-2002
First Named Inventor HUENIG
Group Art Unit 1614
Examiner Name Unassigned
Attorney Docket Number ALBRE-23

RECEIVED
SEP 05 2002
TECHNICAL CENTER 160012900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	6	M. HEZAREEH ET AL., "Differential T Cell Induction of Productive HIV Replication in Samples From Patients on Prolonged Suppressive Therapy", CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS , 1998, pg. 183-Vol. 5	
	7	U. HENGGE ET AL., "Randomized, Controlled Phase II Trial of Subcutaneous Interleukin-2 in Combination With Highly Active Antiretroviral Therapy (Haart) in HIV Patients", 1998, pp. F225-F234, Vol. 12, No. 17	
	8	T-W CHUN ET AL., "Effect of Interleukin-2 on the Pool of Latently Infected, Resting CD4+ T Cells in HIV-1-Infected Patients Receiving Highly Active Anti-Retroviral Therapy", NATURE MEDICINE , June 6, 1999, pp. 651-655, Vol. 5, No. 6	
I.O.	9	T-W CHUN ET AL., "Quantification of Latent Tissue Reservoirs and Total Body Viral Load in HIV-1 Infection", NATURE May 8, 1997, pp 183-188, Vol 387, No. 6629	
	10	E. Barker et al., "CD28 Costimulation Increases CD8+ Cell Suppression of HIV Replication", The JOURNAL OF IMMUNOLOGY , November 15, 1997, pp.51213-5131, Vol. 159, No. 10	

Examiner Signature Lina Ouspeneva Date Considered 11/08/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.